Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of BIVV020 in adults with persistent/chronic immune thrombocytopenia
NL-OMON52011Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of riliprubart in immune thrombocytopenia (ITP), sponsored by Sanofi. Started May 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON52011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52011.